AgingResearch.NewsJoin free
Nature Medicine

Semaglutide lowered pressure in a heart failure group with obesity

Among patients with obesity and heart failure with preserved ejection fraction, exercise pressure fell 9.8 millimeters of mercury with semaglutide versus a 0.9 rise with placebo.

Paper by Barry A. Borlaug, Michael D. Jensen, Milton Packer, +4 more authorsRickey E. Carter
Figure 1 from Nature Medicine
Open the figure at full size
Figure 1. Borlaug et al.

Our read

Interventions
Studied:
Randomized trial in 81 people (52 weeks, double-blind, placebo-controlled, registered NCT05371496)
In the record:
The 677th paper on semaglutide with results in people; 1,706 on record in all.
Why it’s aging research:
It studies an intervention with evidence of extending healthy life.

Editor of record: Boris Djordjevic · AgingResearch.News

Paper
Follow @agingbrief

Eighty-one patients with obesity had heart failure with preserved ejection fraction, meaning the heart still pumped out a normal share of its blood with each beat. They included 47 women and entered a randomized, double-blind trial of semaglutide, 2.4 milligrams weekly, or placebo for 52 weeks.

The main outcome was the change in pulmonary artery wedge pressure during low-intensity exercise. This invasive measurement indicates congestion and pressure as the heart fills. Exercise pressure fell by 9.8 millimeters of mercury with semaglutide, versus a 0.9 rise with placebo. Semaglutide also reduced resting pressure. At 52 weeks, 53.7% of semaglutide patients versus 7.4% of placebo patients had normal pressures at both rest and exercise, meeting the trial’s pressure-based definition of remission.

Why it matters

Heart failure is an age-related disease. The trial helps address how semaglutide may improve symptoms in people who have this form of heart failure alongside obesity.

Caveats

The main outcome measured heart pressure rather than hospitalizations or survival. The trial covered 81 patients with both this form of heart failure and obesity over 52 weeks, limiting its application to other patients or longer-term outcomes.

Where the evidence stands

Semaglutide

Cells, mice and humans: replicated by independent labs. Worms or flies: nothing yet.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 424 independent labs in 62 countries
  • 102 findings against
  • 411 trials, 97 with no results posted
  • Funders: Novo Nordisk and others
  • 381 of 1,525 findings with company ties
  • 215 of 411 trials sponsored by its developers

GLP1R

Cells, mice and humans: a single group. Worms or flies: nothing yet.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

Includes the processes named after it and trials of drugs aimed at it.

  • 31 independent labs in 15 countries
  • 2 findings against
  • 865 trials, 125 with no results posted
  • Funders: National Natural Science Foundation of China and others
  • 6 of 60 findings with company ties
  • 796 of 865 trials sponsored by developers of drugs aimed at it

Comments

Be the first to comment.

More peptides

More on Semaglutide